Dacarbazine
- Generic Name
- Dacarbazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
- Associated Therapies
- -
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 402
- Registration Number
- NCT01763164
- Locations
- 🇺🇸
Harry and Jeannette Weinberg Cancer Institute @Franklin Square, Baltimore, Maryland, United States
🇺🇸The Ohio State University James Cancer Hospital, Columbus, Ohio, United States
🇺🇸St. Luke's Hospital - Allentown Campus, Allentown, Pennsylvania, United States
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 418
- Registration Number
- NCT01721772
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇫🇷Local Institution - 0013, Villejuif, France
🇫🇮Local Institution - 0035, Helsinki, Finland
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 405
- Registration Number
- NCT01721746
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸San Francisco Oncology Associates, San Francciso, California, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01716806
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1334
- Registration Number
- NCT01712490
Bevacizumab vs Dacarbazine in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT01705392
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
- Conditions
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT01704287
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 194
- Registration Number
- NCT01693068
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
🇩🇪Research site, München, Germany
🇺🇸Please contact the US Medical Information in, Rockland, Massachusetts, United States
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT01692678
Dacarbazine and Carmustine in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT01692691
- Locations
- 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.